Who is sponsoring NCT00518453?

NCT00518453 is sponsored by Novartis Vaccines.

What drugs are being tested in NCT00518453?

Interventions: Surface antigen inactivated influenza vaccine.

What is the status of NCT00518453?

NCT00518453 is currently COMPLETED.

Last reviewed 2016-11-30 · How we verify

A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Ph.Eur, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects

NCT00518453 Phase 2 COMPLETED

Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations. Immunogenicity and tolerability of the newly composed vaccines are subject for evaluation in a yearly clinical trial in non-elderly adults and elderly subjects (CPMP/BWP/214/96).

Details

Lead sponsor	Novartis Vaccines
Phase	Phase 2
Status	COMPLETED
Enrolment	129
Start date	2007-07
Completion	2007-08

Conditions

Influenza

Interventions

Surface antigen inactivated influenza vaccine

Primary outcomes

evaluate the antibody response to each influenza vaccine antigen — 21 days post-immunization

Countries

United Kingdom